The Cardiovascular and Interventional Radiological Society of Europe (CIRSE) has launched its CIRSE Registry for LifePearl Microspheres (CIREL), a new European-wide observational study that will gather data on patients with colorectal adenocarcinoma and liver-only or liver-dominant metastatic disease, treated with transarterial chemoembolization (TACE) using LifePearl microspheres (Terumo) loaded with irinotecan in specialist hospitals across Europe.
The study aims to observe and categorise the real-life use of the device in the context of patient’s cancer treatment and will also collect extensive quality-of-life data to learn more about the palliative aspect of TACE. Previous research on LifePearl microspheres included only pre-clinical and pharmacokinetic studies.
Philippe L Pereira, speaking on behalf of CIRSE as co-chairperson of the CIREL Steering Committee, states that “CIREL will greatly contribute to the collection of scientific knowledge and clinical data in one of interventional radiology’s most dynamic and promising fields and help us understand better what could be the potential indications to treat patients with TACE”. Pereira is head of Radiology, Minimally Invasive Therapies and Nuclear Medicine at Klinikum am Gesundbrunnen, Heilbronn, Germany.
